IBN Coverage: D-Wave Quantum (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.
LOS ANGELES, CA - June 20, 2025 (NEWMEDIAWIRE) - D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software, and services, announced that it has signed a memorandum of understanding (MOU) with Yonsei University and Incheon Metropolitan City aimed at accelerating quantum computing adoption in South Korea. Supporting the region's ambition to become a global quantum technology hub, the MOU outlines plans to work together on research, talent development, and use case exploration across biotechnology, materials science and other sectors. The MOU also facilitates the organizations' collaborative efforts towards the acquisition of a D-Wave Advantage2
quantum system at the Yonsei University International Campus in Songdo, Yeonsu-gu, Incheon.
To view the full press release, visit https://ibn.fm/3ezs2
About D-Wave Quantum Inc.
D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers, the world's largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.
Forward Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company's newsroom at https://ibn.fm/QBTS
Forward Looking Statements
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
About IBN
IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients.
IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions.
For more information, please visit www.IBN.fm
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Media Contact
IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
38 minutes ago
- Business Wire
WST截止日期：Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人，一名股東代表在2023年2月16日至2025年2月12日期間購買West Pharmaceutical Services, Inc. (NYSE: WST)證券的投資人提起了集體訴訟。West將自身描述為一家「專注於注射藥物包裝元件、密封解決方案及輸送系統的醫療用品公司」。 如欲瞭解更多資訊，請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ，或致電866-767-3653聯絡我們。 指控內容：Rosen Law Firm正在調查對West Pharmaceutical Services, Inc. (NYSE: WST)在其業務營運方面誤導投資人的指控。 起訴書指稱，在整個集體訴訟期內，被告做出了虛假和誤導性陳述及/或未揭露：(1)儘管聲稱對客戶需求有清晰預判，並將業務阻力歸咎於COVID相關產品的臨時性去庫存，但West實際上在其高利潤率的高價值產品(HVP)組合中持續經歷著顯著的去庫存現象；(2) West的SmartDose裝置雖被標榜為高利潤率的成長型產品，但由於營運效率不彰，對West的利潤率造成了嚴重稀釋；(3)這些利潤率壓力引發了高昂重整活動的風險，包括West退出與長期客戶簽署的持續血糖監測(CGM)合約；以及(4)由於上述原因，被告關於West的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱，當市場瞭解真實詳情後，投資人蒙受了損失。 現在怎麼辦：您可能有資格參與針對West Pharmaceutical Services, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表，則必須在2025年7月7日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動，您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊，請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm：與Rosen Law Firm不同，一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者， Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構，並追究公司高階主管的違法行為責任。自成立以來，Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn： 、Twitter： 或Facebook： 上關注我們，以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Business Wire
an hour ago
- Business Wire
ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Elevance Health, Inc. (NYSE: ELV) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance's guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Elevance Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Insider
2 hours ago
- Business Insider
Jefferies Sticks to Their Buy Rating for Halliburton (HAL)
Jefferies analyst Lloyd Byrne reiterated a Buy rating on Halliburton (HAL – Research Report) today and set a price target of $32.00. The company's shares closed yesterday at $20.57. Confident Investing Starts Here: Byrne covers the Energy sector, focusing on stocks such as Baker Hughes Company, Expand Energy, and Canadian Natural. According to TipRanks, Byrne has an average return of 18.1% and a 50.90% success rate on recommended stocks. In addition to Jefferies, Halliburton also received a Buy from Wells Fargo's Roger Read in a report issued on June 24. However, on June 26, RBC Capital maintained a Hold rating on Halliburton (NYSE: HAL). Based on Halliburton's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.42 billion and a net profit of $204 million. In comparison, last year the company earned a revenue of $5.8 billion and had a net profit of $606 million Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HAL in relation to earlier this year. Last month, Weiss Janet L, a Director at HAL bought 8,550.00 shares for a total of $169,119.00.
